Interleukin-16 (IL-16) gene polymorphisms in Iranian patients with colorectal cancer

Journal of Gastrointestinal and Liver Diseases

Volumn 20, Issue 4, 2011, Pages 371-376

  Azimzadeh, Pedram ^a   Romani, Sara ^a   Mohebbi, Seyed Reza ^a   Kazemian, Shabnam ^a   Vahedi, Mohsen ^a   Almasi, Shohreh ^a   Fatemi, Seyed Reza ^a   Zali, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colorectal cancer; Genetic predisposition to disease; Interleukin 16; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 16;

ADULT; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; EXON; FEMALE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKIN-6; IRAN; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; RISK FACTORS; SEQUENCE ANALYSIS, DNA;

EID: 84055222297     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 iranian colorectal cancer patients. Int J Colorectal Dis 2008; 23: 683-688.
2. Lubbe SJ, Pittman AM, Matijssen C, et al. Evaluation of germline Bmp4 mutation as a cause of colorectal cancer. Hum Mutat 2011; 32(1): E1928-E1938.
3. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 2011; 70(Suppl 1): i104-108.
4. Klampfer L. Cytokines, inflammation and colon cancer. Curr Cancer Drug Targets 2011; 11: 451-464.
5. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett 2004; 208: 1-33.
6. Feghali CA, Wright TM. Cytokines in Acute and Chronic Inflammation. Front Biosci 1997; 1(2): d12-26.
7. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005; 37: 74-85.
8. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets 2008; 9: 375-380.
9. Kim HS. Assignment of human interleukin 16 (IL16) to chromosome 15q26.3 by radiation hybrid mapping. Cytogenet Cell Genet 1999; 84: 93.
10. Gu XJ, Cui B, Zhao ZF, et al. Association of the interleukin (IL)-16 gene polymorphisms with Graves' disease. Clin Immunol 2008; 127: 298-302.
11. Bannert N, Vollhardt K, Asomuddinov B, et al. PDZ Domainmediated interaction of interleukin-16 precursor proteins with myosin phosphatase targeting subunits. J Biol Chem 2003; 278: 42190-42199.
12. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
13. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006; 4: 221-233.
14. Sheu BC, Chang WC, Cheng CY, Lin HH, Chang DY, Huang SC. Cytokine regulation networks in the cancer microenvironment. Front Biosci 2008; 13: 6255-6268.
15. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med 2006; 79: 123-130.
16. YIlmaz V, Yentür SP, Saruhan-Direskeneli G. IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine 2005; 30: 188-194.
17. Lio D, Scola L, Crivello A, et al. Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10- 1082 promoter SNP and its interaction with TNF-A -308 promoter SNP. Journal of medical genetics 2003; 40: 296-299.
18. Gao LB, Rao L, Wang YY, et al. The association of interleukin-16 polymorphisms with IL-16 serum levels and risk of colorectal and gastric cancer. Carcinogenesis 2009; 30: 295-299.
19. Nakayama EE, Wasi C, Ajisawa A, Iwamoto A, Shioda T. A new polymorphism in the promoter region of the human interleukin-16 (IL-16) gene. Genes Immun 2000; 1: 293-294.
20. Khlat M, Cazes MH, Génin E, Guiguet M. Robustness of case-control studies of genetic factors to population stratification: magnitude of bias and type I error. Cancer Epidemiol Biomarkers Prev 2004; 13: 1660-1664.
21. Wang L, Li Q, Li Z, Zheng G. Bayes Factors in the Presence of Population Stratification. Stat Probab Lett 2011; 81:836-841.
22. Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res 2002; 30: 3894-3900.
23. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517.
24. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007; 117: 1175-1183.
25. Park K, Woo M, Nam J, Kim JC. Start codon polymorphisms in the vitamin D receptor and colorectal cancer risk. Cancer Lett 2006; 237: 199-206.
26. Mahmoudi T, Mohebbi SR, Pourhoseingholi MA, Fatemi SR, Zali MR. Vitamin D receptor gene apai polymorphism is associated with susceptibility to colorectal cancer. Dig Dis Sci 2010; 55: 2008-2012.
27. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 287: G7-G17.
28. Mathy NL, Scheuer W, Lanzendörfer M, et al. Interleukin 16 stimulates the expression and production of pro inflammatory cytokines by human monocytes. Immunology 2000; 100: 63-69.
29. Mochizuki Y, Nakanishi H, Kodera Y, et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-Tagged human gastric cancer cell line. Clin Exp Metastasis 2004; 21: 39-47.
30. Muc-Wierzgon M, Nowakowska-Zajdel E, Kokot T, et al. Genetic disregulation of TNF alpha and TNF alpha type II receptors in colon cancer at the II and III stage of disease. J Biol Regul Homeost Agents 2006; 20: 10-14.
31. Apte RN, Dotan S, Elkabets M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006; 25: 387-408.
32. van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006; 11: 397-408.
33. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998; 10: 573-580.
34. Xue H, Gao L, Wu Y, et al. The IL-16 gene polymorphisms and the risk of the systemic lupus erythematosus. Clin Chim Acta 2009; 403: 223-225.
35. Zhu J, Qin C, Yan F, et al. IL-16 polymorphism and risk of renal cell carcinoma: association in a Chinese population. Int J Urol 2010; 17: 700-707.
36. Gao LB, Liang WB, Xue H, et al. Genetic polymorphism of interleukin-16 and risk of nasopharyngeal carcinoma. Clin Chim Acta 2009; 409: 132-135.
37. Gan XL, Lin YH, Zhang Y, Yu TH, Hu LN. Association of an Interleukin-16 Gene Polymorphism with the Risk and Pain Phenotype of Endometriosis. DNA Cell Biol 2010; 29: 663-667.
38. Hosseini-Farahabadi S, Tavakkol-Afshari J, Rafatpanah H, Farid Hosseini R, Khaje Daluei M. Association between the polymorphisms of IL-4 gene promoter (-590C>T), IL-13 coding region (R130Q) and IL-16 gene promoter (-295T>C) and allergic asthma. Iran J Allergy Asthma Immunol 2007; 6: 9-14.